
Opinion|Videos|June 9, 2023
Emerging Evidence on the Treatment of Obesity
In this episode of MEDcast, Diana Isaacs and Natalie Bellini interview Dr. Ken Fujioka, an endocrine specialist, to discuss practice guidelines on obesity treatment and the evolution of anti-obesity medications over the last decade.
Advertisement
Episodes in this series
1:20 Obesity-associated metabolic disturbances
5:37 When to start medication for obesity
8:28 Metabolic pathways leading to weight gain
13:19 Long-term impact of weight fluctuations
16:07 GLP-1 agonists for weight loss
20:26 Insurance coverage for anti-obesity medications (AOMs)
24:50 Combining lifestyle changes with AOMs
26:27 ‘Super-responders’ to GLP-1 agonist therapies
30:51 Non-responders to GLP-1 agonist therapies
37:28 Comprehensive approach to weight management
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Semaglutide 7.2 mg Shows Greater BMI, Cardiometabolic Gains in T2D
5




























































